Village Farms International Reports Second Quarter 2022 Financial Results
Village Farms International, Inc. (“Village Farms” or the “Company”) (NASDAQ: VFF) (TSX: VFF) today announced its financial results for the second quarter ended June 30, 2022. All figures are in U.S. dollars unless otherwise indicated.
Management Commentary
“The continued successful execution of our differentiated Canadian Cannabis strategy drove strong year-over-year and sequential sales growth, achieving a new record high for the second quarter, as well as our 15th consecutive quarter of positive EBITDA for that business,” said Michael DeGiglio, Chief Executive Officer, Village Farms. “Our Pure Sunfarms brand maintained its number one market share position in dried flower in Canada*, while Rose LifeScience became a top-three licensed producer in Quebec, with an 8.5% market share**, in part driven by its Promenade brand in collaboration with Pure Sunfarms. Importantly, our planned investments in our commercial capabilities, including sales support and marketing, strain development and other innovation, new brands and geographical expansion over the past 18 months to drive both near- and long-term growth are beginning to yield their intended results. We are also seeing the benefits of the evolution of our strategy for non-branded, with larger, more regular sales to a smaller number of repeat customers, which has been complemented by steady growth in exports, having recently completed our sixth shipment to Australia.”
– ADVERTISEMENT –
“We continue to expect the second half of 2022 to trend favourably for our Canadian Cannabis business, as we launch new SKUs, including new strains, across our brands into a market that continues to exhibit robust growth. In addition, the roll out of the Original Fraser Valley Weed Co. brand will enable us to address a considerable portion of the Canadian market that we previously did not. We also expect to increasingly benefit from integrating Pure Sunfarms and Rose to realize the significant synergistic opportunities that can take Village Farms’ Canadian Cannabis business to the next level.”
“In our U.S. Cannabis business, Balanced Health Botanicals and CBDistillery® brand continues to perform well amidst a broader U.S. cannabinoid market that continues to be challenged by lack of regulatory clarity, resulting in confusion at the consumer level. Balanced Health is an integral part of our long-term US Cannabis strategy, as a well-established, profitable business, with top brand awareness, and an established e-commerce platform and retail channels that provides another potential pathway to participate in the high-THC cannabis market in the U.S. when we are able.”
“Internationally, we continue to progress steadily on multiple new opportunities in selected target markets. Having received EU GMP certification, our Canadian Cannabis operations are finalizing details with partners with shipments expected to commence in the coming months. Separately today, we announced our ownership of 85% of Leli Holland, which has been was awarded the tenth and final cultivation license granted under the Closed Cannabis Supply Chain Experiment in the Netherlands. As a result, we will directly participate in what will be the first major European market to permit large-scale cannabis cultivation and distribution for recreational purposes, while strongly positioning our Company for success in other European markets as they legalize.”
“In our Village Farms Fresh produce business, as anticipated we continued to be challenged by cost inflation across our operations, with significant year-over-year increases in most categories, including fertilizer and other inputs, packaging, freight and labor costs, which has been exacerbated by the continued impact of the Brown Rugose virus that has impacted the global tomato industry. To date, we have not been able to pass these cost increases on to customers due to the continued oversupply in each of the tomato, cucumber and pepper markets. With the goal of optimizing profitability for Village Farms Fresh, we have initiated an intensive operational review of our operations. We believe strongly in the potential of these operations, especially for their optionality and considerably greater value as part of our cannabis strategy in a national or Texas state legal cannabis market in which we can participate.”
Second Quarter 2022 Financial Highlights
(All comparable periods are for Second Quarter 2021)
Consolidated
Consolidated sales increased 18% year-over-year to $82.9 million from $70.4 million;
Consolidated net loss was ($36.6 million), or ($0.41) per share, which included $29.8 million of impairments to Balanced Health Botanicals’ goodwill and intangible assets, compared with ($4.5 million), or ($0.06) per share; and,
Consolidated adjusted EBITDA was negative ($10.3 million) compared with positive adjusted EBITDA of $1.5 million.
Cannabis
Total Cannabis segment net sales increased 44% year-over-year to $35.6 million, representing 43% of total Village Farms sales; and
Total Cannabis segment adjusted EBITDA was $2.1 million, compared with $7.3 million.
Canadian Cannabis (Pure Sunfarms and Rose LifeScience) Financial Summary for the Three and Six Months Ended June 30, 2022 and June 30, 2021
Canadian Cannabis net sales increased 25% year-over-year to a record $29.8 million (C$38.0 million), with a gross margin of 33% (within the Company’s stated target range) and adjusted EBITDA of $2.7 million (C$3.3 million).
Canadian Cannabis Performance Summary
(millions except % metrics)
Three Months Ended June 30,
2022
2021
Change of C$
C$
US$
C$
US$
Total Gross Sales
$53.8
$42.1
$41.7
$34.0
+29 %
Total Net Sales
$38.0
$29.8
$30.4
$24.7
+25 %
Total Cost of Sales 1
$25.6
$20.1
$18.2
$14.8
+41 %
Gross Margin 1
$12.4
$9.7
$12.2
$9.9
+2 %
Gross Margin % 1
33 %
33 %
40 %
40 %
-19 %
SG&A
$10.9
$8.4
$5.4
$4.4
-103 %
Share-based compensation
$0.3
$0.2
$0.2
$0.2
-45 %
Net income
$2.5
$1.8
$4.0
$3.2
-36 %
Adjusted EBITDA 2
$3.3
$2.7
$9.1
$7.4
-63 %
Adjusted EBITDA Margin 2
9 %
9 %
30 %
30 %
-70 %
(millions except % metrics)
Six Months Ended June 30,
2022
2021
Change of C$
C$
US$
C$
US$
Total Gross Sales
$94.5
$74.2
$72.5
$58.3
+30 %
Total Net Sales
$65.6
$51.6
$52.5
$42.2
+25 %
Total Cost of Sales 1
$43.7
$34.4
$33.8
$27.1
+29 %
Gross Margin 1
$21.9
$17.2
$18.7
$15.1
+17 %
Gross Margin % 1
33 %
33 %
36 %
36 %
-7 %
SG&A
$19.7
$15.3
$10.4
$8.3
-89 %
Share-based compensation
$0.8
$0.6
$1.6
$1.3
+51 %
Net income
$4.1
$2.8
$0.4
$0.4
+935 %
Adjusted EBITDA 2
$6.0
$4.8
$12.2
$9.9
-49 %
Adjusted EBITDA Margin 2
9 %
9 %
23 %
23 %
-59 %
1.
Total cost of sales and gross margin for the three and six months ended June 30, 2022 excludes the C$2,245 (US$1,766) and C$4,839 (US$3,815), respectively, positive inventory adjustment and for the three and six months ended June 30, 2021 excludes the C$145 (US$133) and C$3,824 (US$3,058), respectively, inventory adjustment charge from the revaluation of inventory to fair value at the acquisition date of November 2, 2020.
2.
Adjusted EBITDA is a non-GAAP measure, is not a recognized earnings measure and does not have a standard meaning prescribed in by GAAP. See “Non-GAAP Measures” below.
Canadian Cannabis’ Percent of Sales by Product Group1
Three months ended
June 30,
Six months ended
June 30,
Channel
2022
2021
2022
2021
Retail, Flower
67 %
65 %
67 %
68 %
Retail, Derivatives
4 %
8 %
6 %
10 %
Wholesale, Flower and Trim
29 %
27 %
27 %
22 %
1.
Excludes Rose LifeScience commission-based revenue.
U.S. Cannabis (Balanced Health Botanicals and VF Hemp)
U.S. Cannabis net sales were $5.8 million, with a gross margin of 66% and adjusted EBITDA of negative ($0.6 million). There are no year-over-year comparisons because Balanced Health Botanicals was acquired by Village Farms during the third quarter of 2021 (August 16, 2021).
Village Farms Fresh (Produce)
Sales increased 4% to $47.2 million and adjusted EBITDA was negative ($10.3 million), compared with ($4.0 million), with the magnitude of the adjusted EBITDA loss being due primarily to the impact of inflation on costs.
Strategic Growth and Operational Highlights
Canadian Cannabis
Pure Sunfarms’ maintained its number one brand position for dried flower in Canada and was the number five licensed producer in Canada (by dollar sales), and remained the top-selling brand of dried flower products in key markets of Ontario, Alberta and British Columbia, while continuing to lead publicly traded Canadian cannabis companies in profitability.
Launched Pure Sunfarms branded products in Yukon, Northwest Territories, New Brunswick and Newfoundland and Labrador, extending Pure Sunfarms’ brand reach to ten provinces and territories representing 98 per cent of total legal cannabis sales in Canada.
At the end of the second quarter, Pure Sunfarms began shipping products under its second brand, the Original Fraser Valley Weed Co. (“Fraser Valley”), which quickly sold out in its initial provincial market, British Columbia. Fraser Valley products appeal to the value segment of the market, targeting the frequent, price-conscious consumer with dependable and potent bulk flower.
Rose expanded market share of its brands in Quebec to 8.5%, becoming the third best-selling licensed producer in that province**, supported by its strong portfolio, in particular the Promenade brand.
Canadian Cannabis launched a total of 23 new SKUs (14 by Pure Sunfarms and nine by Rose LifeScience).
Pure Sunfarms and NOYA Cannabis Inc. launched Cookies sun-grown flower in Ontario during the quarter (with Pure Sunfarms being the licensed producer of record).
*
For the quarter ended June 30, 2022. Based on HiFyre data
**
For the quarter ended June 30, 2022. Based on internal calculations, supported by StatsCan data.
U.S. Cannabis
Balanced Health successfully launched the first product in the new Synergy+ line. UNWIND Synergy+ is positioned to help customers unwind after work or a long day.
John Harloe J.D. PhD, General Counsel for Balanced Health, was chosen by the Colorado Department of Public Health and Environment for the SB 22-205 task force. Colorado Governor, Jared Polis, has directed the task force to study intoxicating hemp products, make legislative and rule recommendations and analyze the effectiveness of each recommendation.
Subsequent to June 30, 2022, Balanced Health announced the results of a study that reported participants showed a significant reduction of mild or temporary anxiety when they began using CBDistillery Daytime Synergy CBG + CBD tincture.
International Cannabis
Subsequent to the quarter-end, Leli Holland B.V. (“Leli Holland”) was awarded the tenth and final cultivation license granted under the Dutch Closed Supply Chain Experiment program. Subsequently, Village Farms exercised its previously announced option, acquiring 85% of Leli Holland, enabling it to directly participate as a cultivator and distributor in the Netherlands, the first major European country to permit large scale recreational cultivation.
Pure Sunfarms completed its sixth shipment to Australia as the Australian medical cannabis market continues to experience steady growth.
Pure Sunfarms is completing regulatory processes and other preparations to enable it to begin exporting EU-GMP certified dried flower to additional international medicinal markets, with an initial focus on Israel and Germany, in the coming months.
Village Farms Fresh (Produce)
Initiated an intensive operational review of the Fresh Produce business with the goal of optimizing profitability of the business.
Corporate
Village Farms was named to Corporate Knights’ Inaugural Future 50: The Fastest Growing Sustainable Companies in Canada. Village Farms was selected from a pool of 6,115 companies (1,100 public and 4,015 private) as one of 25 publicly traded companies with the highest year-over-year percentage increase in “clean revenue”.
Presentation of Financial Results
The Company’s financial statements for the three and six months ended June 30, 2022, as well as the comparative periods for 2021, have been prepared and presented under United States Generally Accepted Accounting Principals (“GAAP”). Balanced Health was acquired on August 16, 2021 and their results are presented in the operations of our consolidated wholly-owned subsidiaries for the three and six months ended June 30, 2022. The Company acquired 70% of Rose LifeScience on November 15, 2021 and their results are presented in the operations of our consolidated wholly-owned subsidiaries and the minority interest is presented in Net Income (Loss) Attributable to Non-controlling Interests, Net of Tax for the three and six months ended June 30, 2022.
RESULTS OF OPERATIONS
(In thousands of U.S. dollars, except per share amounts, and unless otherwise noted)
Consolidated Financial Performance
Three Months Ended
June30,
Six Months Ended
June30,
2022 (1)
2021
2022 (1)
2021
Sales
$
82,903
$
70,374
$
153,059
$
122,770
Cost of sales
(76,580)
(65,109)
(136,832)
(115,198)
Gross margin
6,323
5,265
16,227
7,572
Selling, general and administrative expenses
(17,402)
(9,025)
(34,373)
(17,117)
Share-based compensation
(1,114)
(1,887)
(2,078)
(3,885)
Interest expense
(665)
(598)
(1,348)
(1,339)
Interest income
—
46
110
49
Foreign exchange (loss) gain
(527)
193
(208)
(311)
Other expense, net
(30)
(166)
(38)
(235)
Impairments (2)
(29,799)
—
(29,799)
—
Write-off of joint venture loan
(592)
—
(592)
—
Loss on disposal of assets
—
(40)
—
(40)
Recovery of income taxes
9,714
1,781
11,380
3,620
Loss from consolidated entities
(34,092)
(4,431)
(40,719)
(11,686)
Less: net loss attributable to non-controlling interests, net
of tax
152
—
314
—
Loss from equity method investments
(2,615)
(86)
(2,667)
(213)
Net loss attributable to Village Farms International Inc
$
(36,555)
$
(4,517)
$
(43,072)
$
(11,899)
Adjusted EBITDA (3)
$
(10,308)
$
1,547
$
(16,419)
$
1,951
Basic loss per share
$
(0.41)
$
(0.06)
$
(0.49)
$
(0.15)
Diluted loss per share
$
(0.41)
$
(0.06)
$
(0.49)
$
(0.15)
1.
For the three and six months ended June 30, 2022, Balanced Health’s financial results are fully consolidated in the financial results of the Company and Village Farms’ share of Rose LifeScience’s financial results are fully consolidated in the financial results of the Company with the minority non-controlling interest presented in net loss attributable to non-controlling interests, net of tax.
2.
Consists of impairments to goodwill of ($25,159) and intangible assets of ($4,630) that were triggered by inflationary effects on consumer spending, decreases in market capitalization of CBD companies and the continued federal regulation lack of clarity with respect to CBD. See Part 1, Item 1 Note 6 “Goodwill and Intangible Assets” for additional details.
3.
Adjusted EBITDA is not a recognized earnings measure and does not have a standardized meaning prescribed by GAAP. Therefore, Adjusted EBITDA may not be comparable to similar measures presented by other issuers. Management believes that Adjusted EBITDA is a useful supplemental measure in evaluating the performance of the Company because it excludes non-recuring and other items that do not reflect our business performance. Adjusted EBITDA includes the Company’s 70% interest in Rose LifeScience since acquisition and 65% interest in VFH.
We caution that our results of operations for the three and six months ended June 30, 2022 and 2021 may not be indicative of our future performance, particularly in light of the ongoing COVID-19 pandemic. We are currently unable to assess the ultimate impact of the COVID-19 pandemic on our business and our results of operations for future periods.
SEGMENTED RESULTS OF OPERATIONS
(In thousands of U.S. dollars, except per share amounts, and unless otherwise noted)
For the Three Months Ended June 30, 2022
VF Fresh
(Produce)
Cannabis
Canada(1)
Cannabis
U.S.(1)
Clean
Energy
Corporate
Total
Sales
$
47,176
$
29,793
$
5,793
$
141
$
—
$
82,903
Cost of sales
(56,143)
(18,285)
(1,956)
(196)
—
(76,580)
Selling, general and administrative
expenses
(2,808)
(8,397)
(4,262)
(7)
(1,928)
(17,402)
Share-based compensation
—
(219)
(107)
—
(788)
(1,114)
Other expense, net
(402)
(231)
(12)
—
(577)
(1,222)
Write-off of joint venture loan
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
